Authors: Shinnar, S Berg, AT Treiman, DM Hauser, WA Hesdorffer, DC Sackellares, JC Leppik, I Sillanpaa, M Sommerville, KW

Citation: S. Shinnar et al., Status epilepticus and tiagabine therapy: Review of safety data and epidemiologic comparisons, EPILEPSIA, 42(3), 2001, pp. 372-379

Authors: Tariot, PN Schneider, LS Mintzer, JE Cutler, AJ Cunningham, MR Thomas, JW Sommerville, KW

Citation: Pn. Tariot et al., Safety and tolerability of divalproex sodium in the treatment of signs andsymptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial, CURR THER R, 62(1), 2001, pp. 51-67

Authors: Shinnar, S Sommerville, KW

Citation: S. Shinnar et Kw. Sommerville, Tiagabine, PEDIATRIC EPILEPSY: DIAGNOSIS AND THERAPY, SECOND EDITION, 2001, pp. 489-498

Authors: Dodrill, CB Arnett, JL Deaton, R Lenz, GT Sommerville, KW

Citation: Cb. Dodrill et al., Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood, EPILEPSY R, 42(2-3), 2000, pp. 123-132

Authors: Hogan, RE Bertrand, ME Deaton, RL Sommerville, KW

Citation: Re. Hogan et al., Total percentage body weight changes during add-on therapy with tiagabine,carbamazepine and phenytoin, EPILEPSY R, 41(1), 2000, pp. 23-28

Authors: Leppik, IE Gram, L Deaton, R Sommerville, KW

Citation: Ie. Leppik et al., Safety of tiagabine: summary of 53 trials, EPILEPSY R, 33(2-3), 1999, pp. 235-246